Oct 19th, 2022

Today's Late-Breaking Science and Featured Science

Saturday's cutting-edge abstracts seek to change clinical practice and promote findings in heart failure.

Graphic of doctor leaning forward with light symbols coming out

LBS.01. The Main Event: Changing Clinical Practice

Saturday, Nov. 5 | 9:30-10:30 a.m. | Main Event I

Comparative Effectiveness of Torsemide Versus Furosemide in Heart Failure: Primary Results of the TRANSFORM-HF Trial (TRANSFORM-HF)
Chlorthalidone Compared to Hydrochlorothiazide for the Prevention of Cardiovascular Events in Patients With Hypertension (DCP)
A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of Cardiovascular Disease (PROMINENT)

LBS.02. Breakthrough Strategies in the HF Journey

Saturday, Nov. 5 | 3-4 p.m. | Main Event I

First-in-Human in vivo CRISPR/Cas9 Editing of the TTRGene by NTLA-2001 in Patients With Transthyretin Amyloidosis With Cardiomyopathy
A Patient Risk-Based Health System Intervention for Acute Heart Failure Care: The Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial
Early Results of the Patient-Reported Outcome Measurement in Heart Failure Clinic (PRO-HF) Trial
IRONMAN: A Randomized Trial of Intravenous Ferric Derisomaltose in Heart Failure With Reduced Ejection Fraction (IRONMAN)

Learn more about #AHA22 Late-Breaking Science and Featured Science.

audience

Early ablation bests medication in treatment naïve AFib patients

audience shot

First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension

Manesh Patel

#AHA 22 Closing Session: That’s a wrap

Getty Images 1388100332

Congratulations to the winners of the Wellness Challenge and Scavenger Hunt

puppy snugglers

Special Recognition to the Hinsdale Humane Society

audience shot

Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD

LBS 05 panelists

Trials’ results highlight supplement ineffectiveness and potential for novel therapies to lower lipoprotein(a), reduce CKD progression

Medtech

Medtech is getting smarter — and so is patient care

med tech checking fluids in a hospital

New digital hub offers professional education to complement lifelong learning

AHA speaker dais

Uncovering novel approaches in heart failure science

Aha22 Sm 2334

Trial results report on benefits of radial artery for CABG, use of prophylactic methylprednisolone and ECMO for patients in cardiogenic shock

Screen Shot 2022 11 06 At 10 45 03 Am

Science, medicine must be a ‘relentless force’ in fighting misinformation